Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022

Rhea-AI Summary

Arcellx, Inc. (NASDAQ: ACLX) announced the presentation of pre-clinical data for ACLX-002, a CD123-targeted CAR-T cell therapy aimed at treating relapsed or refractory Acute Myeloid Leukemia (AML), at the American Association for Cancer Research Annual Meeting 2022. ACLX-002 offers controllability through a dose-dependent activation mechanism, addressing patient-specific disease variations and reducing the risk of adverse events. The presentation is scheduled for April 10, 2022, at the New Orleans Convention Center, highlighting the company's commitment to advancing innovative cancer therapies.

Positive

• Presentation of pre-clinical data for ACLX-002 at a significant cancer research conference.
• ACLX-002's controllable and adaptable treatment approach may improve safety and efficacy for AML patients.

Negative

• None.

FOSTER CITY, Calif., March 8, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the upcoming presentation at the American Association for Cancer Research Annual Meeting 2022 of pre-clinical data for ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory Acute Myeloid Leukemia (AML). ACLX-002 can be activated in a dose dependent manner in vivo with soluble protein adapters allowing for controllability and adaptability to address intra-and inter-patient disease heterogeneity and off-target antigen expression that are often associated with serious dose-limiting adverse events in AML.

Details of the Presentation are as Follows:

Session Category:              Immunology
Session Title:                       Adoptive Cell Therapy 2
Session Date and Time:   Sunday, April 10, 2022, 1:30 PM - 5:00 PM
Location:                              New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Poster Board Number:     22
Permanent Abstract Number: 587 

About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx's lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.

Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia. Visit www.arcellx.com for more information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including Arcellx's expectations regarding the timing of clinical trials for its product candidates. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled "Risk Factors" in documents that Arcellx files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor and Media Contact:
Myesha Lacy
Arcellx, Inc.
ir@arcellx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/arcellx-announces-pre-clinical-data-presentation-for-aclx-002-a-novel-cd123-targeted-universal-car-t-cell-therapy-for-relapsed-or-refractory-acute-myeloid-leukemia-at-the-american-association-for-cancer-research-annual-meeting-20-301498455.html

SOURCE Arcellx, Inc

FAQ

What is ACLX-002?

ACLX-002 is a novel CD123-targeted CAR-T cell therapy developed by Arcellx for treating relapsed or refractory Acute Myeloid Leukemia.

When is the presentation for ACLX-002?

The presentation for ACLX-002 will take place on April 10, 2022, at the American Association for Cancer Research Annual Meeting.

What are the main benefits of ACLX-002?

ACLX-002 offers dose-dependent activation and controllability, potentially reducing adverse events associated with other therapies.

Where will the presentation of ACLX-002 occur?

The presentation will be held at the New Orleans Convention Center in Exhibit Halls D-H, Poster Section 37.

How does ACLX-002 address patient-specific disease variations?

ACLX-002's design allows for adaptability to intra-and inter-patient disease heterogeneity, enhancing its therapeutic approach.